학술논문
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
Document Type
Article
Author
Source
In: Journal for ImmunoTherapy of Cancer . (Journal for ImmunoTherapy of Cancer, 30 November 2023, 11(11))
Subject
Language
English
ISSN
20511426